Bypassing phase 1 trials in the cancer drug development paradigm: Generally unwise and potentially dangerous

Authors
Publication date
Publisher
'Wiley'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.1002%2Fcncr.25543
      Last time updated on 24/03/2021